Company profile for Genethon

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Genethon’s mission is to design gene therapy products for rare diseases, and to ensure their pre-clinical and clinical development in order to provide patients with access to these innovative treatments. To meet this challenge, Genethon has acquired the technical and human resources needed to accelerate the medical application of scientific discoveries arising from fundamental research. Our translational research programs ar...
Genethon’s mission is to design gene therapy products for rare diseases, and to ensure their pre-clinical and clinical development in order to provide patients with access to these innovative treatments. To meet this challenge, Genethon has acquired the technical and human resources needed to accelerate the medical application of scientific discoveries arising from fundamental research. Our translational research programs are supported by a first-rate technological platform and nearly 200 people (researchers, Pharm.Ds, M.Ds, Ph.Ds, engineers and technicians,…) who have joincliniced forces in order to develop these innovative treatments.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
France
Address
Address
1 rue de l’Internationale BP 60 91002 Evry Cedex
Telephone
Telephone
+33 (0) 1 69 47 28 28
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20251009554793/en/Genethon-Confirms-2-Year-Efficacy-in-Duchenne-Muscular-Dystrophy-Patients-Treated-With-Its-Low-Dose-Micro-Dystrophin-Gene-Therapy-GNT0004-at-the-ESGCT-32nd-Annual-Congress

BUSINESSWIRE
09 Oct 2025

https://www.businesswire.com/news/home/20250728691722/en/Genethon-to-Launch-Pivotal-Trial-in-Europe-of-GNT0004-a-Low-Dose-Microdystrophin-Gene-Therapy-for-Duchenne-Muscular-Dystrophy

BUSINESSWIRE
28 Jul 2025

https://www.prnewswire.com/news-releases/hansa-biopharma-reports-second-quarter-and-interim-january-june-2025-financial-results-302507679.html

PR NEWSWIRE
17 Jul 2025

https://www.businesswire.com/news/home/20250619068234/en/Clinical-Milestones-Vector-Innovation-Key-to-Gene-Therapy-GenoTher-Bioclusters-First-International-Summit-Atamyo-Therapeutics-Progress-for-LGMDs-Highlight-Genethons-Most-Recent-Newsletter

BUSINESSWIRE
19 Jun 2025

https://www.businesswire.com/news/home/20250519497866/en/Genethon-Presents-Two-Year-Consolidated-Results-of-Its-Gene-Therapy-Trial-for-Duchenne-Muscular-Dystrophy-Maintenance-of-Motor-Functions-and-Significant-Sustained-Reduction-in-CPK-Levels-in-Patients-Treated-at-the-Effective-Dose-at-ASGCT-2025

BUSINESSWIRE
19 May 2025

https://www.prnewswire.com/news-releases/hansa-biopharma-reports-first-quarter-and-interim-january-march-2025-financial-results-302436980.html

PR NEWSWIRE
24 Apr 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty